JP2017510572A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510572A5
JP2017510572A5 JP2016556962A JP2016556962A JP2017510572A5 JP 2017510572 A5 JP2017510572 A5 JP 2017510572A5 JP 2016556962 A JP2016556962 A JP 2016556962A JP 2016556962 A JP2016556962 A JP 2016556962A JP 2017510572 A5 JP2017510572 A5 JP 2017510572A5
Authority
JP
Japan
Prior art keywords
compound
aliphatic
present
alkyl
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510572A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/020582 external-priority patent/WO2015138986A1/en
Publication of JP2017510572A publication Critical patent/JP2017510572A/ja
Publication of JP2017510572A5 publication Critical patent/JP2017510572A5/ja
Pending legal-status Critical Current

Links

JP2016556962A 2014-03-13 2015-03-13 Fxrアゴニストならびに作製および使用のための方法 Pending JP2017510572A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461952754P 2014-03-13 2014-03-13
US61/952,754 2014-03-13
US201462061463P 2014-10-08 2014-10-08
US62/061,463 2014-10-08
PCT/US2015/020582 WO2015138986A1 (en) 2014-03-13 2015-03-13 Fxr agonists and methods for making and using

Publications (2)

Publication Number Publication Date
JP2017510572A JP2017510572A (ja) 2017-04-13
JP2017510572A5 true JP2017510572A5 (https=) 2017-06-29

Family

ID=54072502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016556962A Pending JP2017510572A (ja) 2014-03-13 2015-03-13 Fxrアゴニストならびに作製および使用のための方法

Country Status (6)

Country Link
EP (1) EP3116878A4 (https=)
JP (1) JP2017510572A (https=)
KR (1) KR20160132111A (https=)
AU (1) AU2015229072A1 (https=)
CA (1) CA2942403A1 (https=)
WO (1) WO2015138986A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
US10703712B2 (en) 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2017078928A1 (en) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
MX385718B (es) * 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA3252823A1 (en) * 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
PE20190972A1 (es) * 2016-09-14 2019-07-09 Novartis Ag Combinacion de agonistas de fxr
KR20190117632A (ko) 2017-02-21 2019-10-16 장피트 Ppar 효현제와 fxr 효현제의 병용
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
AU2019344903B2 (en) 2018-09-18 2025-02-27 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
KR20220038368A (ko) 2019-07-23 2022-03-28 노파르티스 아게 Fxr 작용제를 이용하는 간 질환의 병용 치료
WO2021014349A1 (en) 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
JP7663559B2 (ja) 2019-09-03 2025-04-16 ノバルティス アーゲー Actrii受容体拮抗薬を含む肝疾患または肝臓障害の治療
CN114401745A (zh) 2019-09-19 2022-04-26 诺华股份有限公司 包含fxr激动剂的治疗
WO2021064575A1 (en) 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
KR20220119424A (ko) 2019-12-20 2022-08-29 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
KR20220155356A (ko) 2020-03-18 2022-11-22 메타크린, 인크. 파르네소이드 x 수용체 효능제의 결정형
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Hbv感染の処置のためのfxrアゴニストとifnの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
CN120698876A (zh) * 2025-06-03 2025-09-26 上海埃思凯特科技有限公司 一种吉非罗齐氘代衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス, インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
EP2575821B1 (en) * 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CA2842707A1 (en) * 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis

Similar Documents

Publication Publication Date Title
JP2017510572A5 (https=)
WO2015138986A1 (en) Fxr agonists and methods for making and using
JP7665619B2 (ja) 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤
TWI358296B (en) Acid secretion inhibitor
JP6632532B2 (ja) オートタキシン阻害活性を有するピリミジノン誘導体
KR102810978B1 (ko) 파르네소이드 x 수용체 효능제 및 그의 용도
CN113056264A (zh) 法尼醇x受体激动剂及其用途
WO2017078928A1 (en) Fxr agonists and methods for making and using
TW200900064A (en) Pyrrole compounds
AU2015229055A1 (en) Analogs of fexaramine and methods of making and using
WO2020061118A1 (en) Farnesoid x receptor agonists and uses thereof
KR102433588B1 (ko) 할로겐 치환 헤테로환 화합물의 염
WO2009147170A2 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
CN113056265A (zh) 法尼醇x受体激动剂及其用途
CN112955448A (zh) 芳环或芳杂环类化合物及其制备方法和医药用途
AU2017293271A1 (en) Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof
IL189666A (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
CN104203236A (zh) 杂环酰胺衍生物和含有其的药物
TWI893238B (zh) 二氯酚hsd17b13抑制劑及其用途
WO2010007943A1 (ja) 含窒素複素環化合物
RS57406B1 (sr) Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak
CA2470427A1 (en) Compositions and methods for treating heart failure
JP2005514432A5 (https=)
TW202337449A (zh) 2-取代噻唑hsd17b13抑制劑及其用途
WO2016159576A2 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법